US FDA expands use of J&J's Caplyta as add-on depression drug

Core Insights - The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta for adults with major depressive disorder as an add-on treatment [1] Company Summary - Johnson & Johnson's Caplyta has received FDA approval for an expanded indication, which may enhance its market potential and revenue opportunities in the mental health treatment sector [1]